Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology.

The Ochsner journal

Ma J, Gimenez JM, Sandow T, Devun D, Kirsch D, Gulotta P, Gilbert P, Kay D.
PMID: 29230127
Ochsner J. 2017;17(4):412-416.

BACKGROUND: Since the early 1990s, the minimally invasive image-guided therapies used in interventional oncology to treat hepatocellular carcinoma have continued to evolve. Additionally, the range of applications has been expanded to the treatment of hepatic metastases from colorectal cancer,...

Cite
Ma J, Gimenez JM, Sandow T, et al. Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology. Ochsner J. 2017;17(4):412-416
Ma, J., Gimenez, J. M., Sandow, T., Devun, D., Kirsch, D., Gulotta, P., Gilbert, P., & Kay, D. (2017). Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology. The Ochsner journal, 17(4), 412-416.
Ma, Jenson, et al. "Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology." The Ochsner journal vol. 17,4 (2017): 412-416.
Ma J, Gimenez JM, Sandow T, Devun D, Kirsch D, Gulotta P, Gilbert P, Kay D. Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology. Ochsner J. 2017;17(4):412-416. PMID: 29230127; PMCID: PMC5718455.
Copy Download .nbib Format: NLM
TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.

JMIR research protocols

Chauhan N, Mulcahy MF, Salem R, Benson Iii AB, Boucher E, Bukovcan J, Cosgrove D, Laframboise C, Lewandowski RJ, Master F, El-Rayes B, Strosberg JR, Sze DY, Sharma RA.
PMID: 30664496
JMIR Res Protoc. 2019 Jan 17;8(1):e11545. doi: 10.2196/11545.

BACKGROUND: Colorectal cancer is one of the most common cancers and causes of cancer-related death. Up to approximately 70% of patients with metastatic colorectal cancer (mCRC) have metastases to the liver at initial diagnosis. Second-line systemic treatment in mCRC...

Cite
Chauhan N, Mulcahy MF, Salem R, et al. TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR Res Protoc. 2019;8(1):e11545doi: 10.2196/11545.
Chauhan, N., Mulcahy, M. F., Salem, R., Benson Iii, A. B., Boucher, E., Bukovcan, J., Cosgrove, D., Laframboise, C., Lewandowski, R. J., Master, F., El-Rayes, B., Strosberg, J. R., Sze, D. Y., & Sharma, R. A. (2019). TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR research protocols, 8(1), e11545. https://doi.org/10.2196/11545
Chauhan, Nikhil, et al. "TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial." JMIR research protocols vol. 8,1 (2019): e11545. doi: https://doi.org/10.2196/11545
Chauhan N, Mulcahy MF, Salem R, Benson Iii AB, Boucher E, Bukovcan J, Cosgrove D, Laframboise C, Lewandowski RJ, Master F, El-Rayes B, Strosberg JR, Sze DY, Sharma RA. TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR Res Protoc. 2019 Jan 17;8(1):e11545. doi: 10.2196/11545. PMID: 30664496; PMCID: PMC6354199.
Copy Download .nbib Format: NLM
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC).

Expert review of pharmacoeconomics & outcomes research

Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D.
PMID: 34488517
Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):147-154. doi: 10.1080/14737167.2021.1973892. Epub 2021 Sep 06.

INTRODUCTION: While essential for cost-effectiveness analyses, there are no current resource use and cost data available for advanced hepatocellular carcinoma (HCC) and selective internal radiation therapy (SIRT). The study aims to assess current resource use and costs in HCC...

Cite
Muszbek N, Evans R, Remak E, et al. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Rev Pharmacoecon Outcomes Res. 2021;22(1):147-154doi: 10.1080/14737167.2021.1973892.
Muszbek, N., Evans, R., Remak, E., Brennan, V. K., Colaone, F., Shergill, S., Ross, P., & Mullan, D. (2022). Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert review of pharmacoeconomics & outcomes research, 22(1), 147-154. https://doi.org/10.1080/14737167.2021.1973892
Muszbek, Noemi, et al. "Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)." Expert review of pharmacoeconomics & outcomes research vol. 22,1 (2022): 147-154. doi: https://doi.org/10.1080/14737167.2021.1973892
Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):147-154. doi: 10.1080/14737167.2021.1973892. Epub 2021 Sep 06. PMID: 34488517.
Copy Download .nbib Format: NLM
The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy.

Molecular imaging and radionuclide therapy

Volkan-Salancı B, Bozkurt MF, Peynircioğlu B, Cil B, Uğur O.
PMID: 24416626
Mol Imaging Radionucl Ther. 2013 Dec;22(3):98-102. doi: 10.4274/Mirt.77487. Epub 2013 Dec 10.

OBJECTIVE: Hepatic artery perfusion scintigraphy is a routine procedure for patient evaluation before Y-90 radiomicrosphere therapy and mostly used for prediction of extrahepatic leakage. Moreover, it also displays perfusion pattern of tumours, which is an important parameter on success...

Cite
Volkan-Salancı B, Bozkurt MF, Peynircioğlu B, et al. The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy. Mol Imaging Radionucl Ther. 2013;22(3):98-102doi: 10.4274/Mirt.77487.
Volkan-Salancı, B., Bozkurt, M. F., Peynircioğlu, B., Cil, B., & Uğur, O. (2013). The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy. Molecular imaging and radionuclide therapy, 22(3), 98-102. https://doi.org/10.4274/Mirt.77487
Volkan-Salancı, Bilge, et al. "The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy." Molecular imaging and radionuclide therapy vol. 22,3 (2013): 98-102. doi: https://doi.org/10.4274/Mirt.77487
Volkan-Salancı B, Bozkurt MF, Peynircioğlu B, Cil B, Uğur O. The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy. Mol Imaging Radionucl Ther. 2013 Dec;22(3):98-102. doi: 10.4274/Mirt.77487. Epub 2013 Dec 10. PMID: 24416626; PMCID: PMC3888020.
Copy Download .nbib Format: NLM
Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.

Journal of hepatocellular carcinoma

Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ.
PMID: 34909425
J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021.

BACKGROUND: Both trans-arterial radioembolization (TARE) and conventional trans-arterial chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE and conventional TACE as the initial trans-arterial...

Cite
Kim MA, Jang H, Choi NR, et al. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021;8:1565-1577doi: 10.2147/JHC.S335879.
Kim, M. A., Jang, H., Choi, N. R., Nam, J. Y., Lee, Y. B., Cho, E. J., Lee, J. H., Yu, S. J., Kim, H. C., Chung, J. W., Yoon, J. H., & Kim, Y. J. (2021). Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of hepatocellular carcinoma, 81565-1577. https://doi.org/10.2147/JHC.S335879
Kim, Minseok Albert, et al. "Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study." Journal of hepatocellular carcinoma vol. 8 (2021): 1565-1577. doi: https://doi.org/10.2147/JHC.S335879
Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021. PMID: 34909425; PMCID: PMC8665867.
Copy Download .nbib Format: NLM
Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.

Journal of hepatocellular carcinoma

Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ.
PMID: 34909425
J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021.

BACKGROUND: Both trans-arterial radioembolization (TARE) and conventional trans-arterial chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE and conventional TACE as the initial trans-arterial...

Cite
Kim MA, Jang H, Choi NR, et al. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021;8:1565-1577doi: 10.2147/JHC.S335879.
Kim, M. A., Jang, H., Choi, N. R., Nam, J. Y., Lee, Y. B., Cho, E. J., Lee, J. H., Yu, S. J., Kim, H. C., Chung, J. W., Yoon, J. H., & Kim, Y. J. (2021). Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of hepatocellular carcinoma, 81565-1577. https://doi.org/10.2147/JHC.S335879
Kim, Minseok Albert, et al. "Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study." Journal of hepatocellular carcinoma vol. 8 (2021): 1565-1577. doi: https://doi.org/10.2147/JHC.S335879
Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021. PMID: 34909425; PMCID: PMC8665867.
Copy Download .nbib Format: NLM
Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma.

Journal of gastrointestinal oncology

Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM.
PMID: 27284477
J Gastrointest Oncol. 2016 Jun;7(3):433-40. doi: 10.21037/jgo.2015.10.04.

BACKGROUND: Non-operative treatment for hepatocellular carcinoma (HCC) has expanded significantly with the use of selective internal radiotherapy (SIRT) mostly with yttrium 90 ((90)Y) tagged microspheres and highly conformal external beam radiation therapy such as stereotactic body radiotherapy (SBRT) to...

Cite
Oladeru OT, Miccio JA, Yang J, et al. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol. 2016;7(3):433-40doi: 10.21037/jgo.2015.10.04.
Oladeru, O. T., Miccio, J. A., Yang, J., Xue, Y., Ryu, S., & Stessin, A. M. (2016). Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. Journal of gastrointestinal oncology, 7(3), 433-40. https://doi.org/10.21037/jgo.2015.10.04
Oladeru, Oluwadamilola T, et al. "Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma." Journal of gastrointestinal oncology vol. 7,3 (2016): 433-40. doi: https://doi.org/10.21037/jgo.2015.10.04
Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol. 2016 Jun;7(3):433-40. doi: 10.21037/jgo.2015.10.04. PMID: 27284477; PMCID: PMC4880776.
Copy Download .nbib Format: NLM
Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.

Journal of gastrointestinal oncology

Kennedy A, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kaiser A, Nutting CW, Rose SC, Wang EA, Savin MA.
PMID: 28890810
J Gastrointest Oncol. 2017 Aug;8(4):614-624. doi: 10.21037/jgo.2017.03.10.

RESULTS: Dates of death were obtained for 574 out of a total of 606 patients, and overall survival (OS) data analyzed. Updated median OS was 10.0 months (95% CI: 9.2-11.8 months) at a median follow-up of 9.5 months versus...

Cite
Kennedy A, Cohn M, Coldwell DM, et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol. 2017;8(4):614-624doi: 10.21037/jgo.2017.03.10.
Kennedy, A., Cohn, M., Coldwell, D. M., Drooz, A., Ehrenwald, E., Kaiser, A., Nutting, C. W., Rose, S. C., Wang, E. A., & Savin, M. A. (2017). Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. Journal of gastrointestinal oncology, 8(4), 614-624. https://doi.org/10.21037/jgo.2017.03.10
Kennedy, Andrew, et al. "Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases." Journal of gastrointestinal oncology vol. 8,4 (2017): 614-624. doi: https://doi.org/10.21037/jgo.2017.03.10
Kennedy A, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kaiser A, Nutting CW, Rose SC, Wang EA, Savin MA. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol. 2017 Aug;8(4):614-624. doi: 10.21037/jgo.2017.03.10. PMID: 28890810; PMCID: PMC5582033.
Copy Download .nbib Format: NLM
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.

JMIR research protocols

Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R.
PMID: 30111528
JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234.

BACKGROUND: Globally, hepatocellular carcinoma is the second most common cause of cancer deaths. It remains challenging to intensify cancer treatment without impairing liver function.OBJECTIVE: The objective of the TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (STOP-HCC)...

Cite
Chauhan N, Bukovcan J, Boucher E, et al. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc. 2018;7(8):e11234doi: 10.2196/11234.
Chauhan, N., Bukovcan, J., Boucher, E., Cosgrove, D., Edeline, J., Hamilton, B., Kulik, L., Master, F., & Salem, R. (2018). Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR research protocols, 7(8), e11234. https://doi.org/10.2196/11234
Chauhan, Nikhil, et al. "Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial." JMIR research protocols vol. 7,8 (2018): e11234. doi: https://doi.org/10.2196/11234
Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234. PMID: 30111528; PMCID: PMC6115595.
Copy Download .nbib Format: NLM
Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.

Journal of hepatocellular carcinoma

Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ.
PMID: 34909425
J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021.

BACKGROUND: Both trans-arterial radioembolization (TARE) and conventional trans-arterial chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE and conventional TACE as the initial trans-arterial...

Cite
Kim MA, Jang H, Choi NR, et al. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021;8:1565-1577doi: 10.2147/JHC.S335879.
Kim, M. A., Jang, H., Choi, N. R., Nam, J. Y., Lee, Y. B., Cho, E. J., Lee, J. H., Yu, S. J., Kim, H. C., Chung, J. W., Yoon, J. H., & Kim, Y. J. (2021). Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of hepatocellular carcinoma, 81565-1577. https://doi.org/10.2147/JHC.S335879
Kim, Minseok Albert, et al. "Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study." Journal of hepatocellular carcinoma vol. 8 (2021): 1565-1577. doi: https://doi.org/10.2147/JHC.S335879
Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021. PMID: 34909425; PMCID: PMC8665867.
Copy Download .nbib Format: NLM
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC).

Expert review of pharmacoeconomics & outcomes research

Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D.
PMID: 34488517
Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 06;1-8. doi: 10.1080/14737167.2021.1973892. Epub 2021 Sep 06.

INTRODUCTION: While essential for cost-effectiveness analyses, there are no current resource use and cost data available for advanced hepatocellular carcinoma (HCC) and selective internal radiation therapy (SIRT). The study aims to assess current resource use and costs in HCC...

Cite
Muszbek N, Evans R, Remak E, et al. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Rev Pharmacoecon Outcomes Res. 2021;1-8doi: 10.1080/14737167.2021.1973892.
Muszbek, N., Evans, R., Remak, E., Brennan, V. K., Colaone, F., Shergill, S., Ross, P., & Mullan, D. (2021). Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert review of pharmacoeconomics & outcomes research, 1-8. https://doi.org/10.1080/14737167.2021.1973892
Muszbek, Noemi, et al. "Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)." Expert review of pharmacoeconomics & outcomes research vol. (2021): 1-8. doi: https://doi.org/10.1080/14737167.2021.1973892
Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 06;1-8. doi: 10.1080/14737167.2021.1973892. Epub 2021 Sep 06. PMID: 34488517.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries